CTOs on the Move

Analgesic Solutions

www.analgesicsolutions.com

 
Analgesic Solutions, LLC., founded in 2006, is a privately held consulting company and Clinical Research Organization. We are a hands-on team of experts across a variety of disciplines who consult on and conduct clinical trials aimed at bringing important new pain treatments to market. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the premier choice for providing assistance and training to insure successful pain trials. Clients come to us when looking to develop and commercialize better treatments for pain. Our team, with Nathaniel Katz M.D., M.S., serving as our foremost expert, helps ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Arturo Morales
 Chief Technology Officer Profile

Similar Companies

Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.

Global Pharmaceutical Sourcing

Global Pharmaceutical Sourcing is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cobb Psychotherapy LCSW

Cobb Psychotherapy is a group private practice providing mental health counseling services. Our therapists practice a range of interventions including evidence-based therapies traditional talk therapy.

Rib-X Pharmaceuticals

Rib-X Pharmaceuticals, Inc. is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inversago Pharma

A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).